Exavir Therapeutics Receives $3 Million Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110

Media Type
Article
Publish or Event Date
Research Institution
Exavir Therapeutics
Short Title
Exavir Therapeutics Receives $3 Million Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110
Content Coordinator